NRX Pharmaceuticals paid its 5 named executives $2.0M in total in FY2024 (Dec). CEO Jonathan Javitt was paid $825.0K of that.
Pay$100 in the stock at the end of FY22 → $20
Pay of each named executive
Jonathan JavittChief Executive Officer, Chief Scientist and Chairman
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
2 years
Richard NaridoFormer Chief Financial Officer
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
2 years
Stephen WillardFormer Chief Executive Officer
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
2 years
Matthew DuffyChief Business Officer
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
2 years
Michael AbramsChief Financial Officer
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
2 years
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.